Reinforcing its commitment to oncology, Boehringer Ingelheim has agreed to acquire NBE-Therapeutics in a deal worth up to US$1.43 B (€1.18 B). The deal marks Boehringer’s entrance into the antibody-drug conjugate therapy space and gives it access to NBE’s lead candidate NBE-002, an anti-ROR1 antibody in Phase I/II development for the treatment of triple negative breast cancer, lung cancer and ovarian cancer. Interestingly, the deal comes just one day after Boehringer agreed to acquire Labor Dr. Merk & Kollegenin a bid to strengthen its immuno-oncology and cancer vaccine platforms.